The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Highly prevalent TERT promoter mutations in aggressive thyroid cancers
Open accessAbstract
Mutations 1 295 228 C>T and 1 295 250 C>T (termed C228T and C250T respectively), corresponding to −124 C>T and −146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase ( TERT ) gene, have recently been reported in human cancers, but not in thyroid cancers yet. We explored these mutations in thyroid cancers by genomic sequencing of a large number of primary tumor samples. We found the C228T mutation in 0 of 85 (0.0%) benign thyroid tumors, 30 of 257 (11.7%) papillary thyroid cancers (PTC), 9 of 79 (11.4%) follicular thyroid cancers (FTC), 3 of 8 (37.5%) poorly differentiated thyroid cancers (PDTC), 23 of 54 (42.6%) anaplastic thyroid cancers (ATC), and 8 of 12 (66.7%) thyroid cancer cell lines. The C250T mutation was uncommon, but mutually exclusive with the C228T mutation, and the two mutations were collectively found in 11 of 79 (13.9%) FTC, 25 of 54 (46.3%) ATC, and 11 of 12 (91.7%) thyroid cancer cell lines. Among PTC variants, the C228T mutation was found in 4 of 13 (30.8%) tall-cell PTC (TCPTC), 23 of 187 (12.3%) conventional PTC, and 2 of 56 (3.6%) follicular variant PTC samples. No TERT mutation was found in 16 medullary thyroid cancer samples. The C228T mutation was associated with the BRAF V600E mutation in PTC, being present in 19 of 104 (18.3%) BRAF mutation-positive PTC vs 11 of 153 (7.2%) the BRAF mutation-negative PTC samples ( P =0.0094). Conversely, BRAF mutation was found in 19 of 30 (63.3%) C228T mutation-positive PTC vs 85 of 227 (37.4%) C228T mutation-negative PTC samples ( P =0.0094). We thus for the first time, to our knowledge, demonstrate TERT promoter mutations in thyroid cancers, that are particularly prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Self-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationBRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Self-citationAssociation Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Self-citationAmerican Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Integration of MAP Kinase Signal Transduction Pathways at the Serum Response Element
Whitmarsh, A. J., Shore, P., Sharrocks, A. D., & Davis, R. J. (1995) · Science · doi:10.1126/science.7618106 · Cited by 932
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Self-citationHu, S., Liu, D., Tufano, R. P., Carson, K. A., Rosenbaum, E., Cohen, Y., Holt, E. H., Kiseljak‐Vassiliades, K., Rhoden, K. J., Tolaney, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22110 · Cited by 197
Self-citationGhossein, R. A., Leboeuf, R., Patel, K. N., Rivera, M., Katabi, N., Carlson, D. L., Tallini, G., Shaha, A. R., Singh, B., & Tuttle, R. M. (2007) · Thyroid · doi:10.1089/thy.2007.0061 · Cited by 141
Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma
Liu, X., Wu, G., Shan, Y., Hartmann, C. J., von Deimling, A., & Xing, M. (2013) · Cell Cycle · doi:10.4161/cc.24662 · Cited by 132
Self-citationTelomerase and the search for the end of cancer
D, S. M. M., Pooley, K. A., & Nitti, D. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.006 · Cited by 126
van Staveren, W. C. G., Solís, D. W., Delys, L., Duprez, L., Andry, G., Franc, B., Thomas, G., Libert, F., Dumont, J. E., Detours, V., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4026 · Cited by 123
SAP1a is a nuclear target of signaling cascades involving ERKs.
Janknecht, R., Ernst, W. H., & Nordheim, A. (1995) · PubMed · Cited by 85
Strahl, T., Gille, H., & Shaw, P. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11563 · Cited by 65
The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer
Xing, M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02332.x · Cited by 39
Self-citationTelomerase RNA biosynthesis and processing
Smekalova, E. M., Shubernetskaya, O. S., Zvereva, M. I., Gromenko, E. V., Rubtsova, M. P., & Донцова, О. А. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912100045 · Cited by 36
Capezzone, M., Marchisotta, S., Cantara, S., & Pacini, F. (2009) · Current Genomics · doi:10.2174/138920209789503897 · Cited by 22
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Overview of the 2022 WHO Classification of Thyroid Neoplasms
Baloch, Z. W., Asa, S. L., Barletta, J. A., Ghossein, R. A., Juhlin, C. C., Jung, C. K., LiVolsi, V. A., Papotti, M. G., Sobrinho-Simões, M., Tallini, G., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09707-3 · Cited by 1,158
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Xing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Self-citation
Metadata
- Authors
- Liu, X., Bishop, J., Shan, Y., Pai, S., Liu, D., Murugan, A. K., Sun, H., El-Naggar, A. K., & Xing, M.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2013-06-13
- Volume
- 20
- Issue
- 4
- Pages
- 603-610
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2103523670
- Cited by
- 613
- References
- 22
- FWCI
- 37.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.